Table 1.
Demographics and clinical characteristics of rheumatic disease patients with COVID-19 over calendar time.
| Time period | ||||||
|---|---|---|---|---|---|---|
| Overall (n=1449) | Early COVID-19 | Early treatment | Early vaccination | Additional vaccination and Delta wave | Omicron wave | |
| 1 March 2020–30 June 30 (n=261) | 1 July 2020–31 January 2021 (n=492) | 1 February 2021–30 June 2021 (n=123) | 1 July 2021–16 December 2021 (n=172) | 17 December 2021–31 January 2022 (n=401) | ||
| Age, years (mean±SD) | 58.4 (17.5) | 63.1 (16.6) | 59.3 (17.0) | 55.5 (16.9) | 56.8 (17.7) | 54.2 (17.6) |
| Female sex, n (%) | 1090 (75.2) | 196 (75.1) | 370 (75.2) | 90 (73.2) | 111 (64.5) | 323 (80.5) |
| Race, n (%) | ||||||
| White | 1035 (71.4) | 154 (59.0) | 353 (71.7) | 93 (75.6) | 136 (79.1) | 299 (74.6) |
| Black | 162 (11.2) | 52 (19.9) | 50 (10.2) | 15 (12.2) | 11 (6.4) | 34 (8.5) |
| Asian, Hawaiian or Pacific Islander | 52 (3.6) | 9 (3.4) | 19 (3.9) | 6 (4.9) | 7 (4.1) | 11 (2.7) |
| Other or unknown | 200 (13.8) | 46 (17.6) | 70 (14.2) | 9 (7.3) | 18 (10.5) | 57 (14.2) |
| Hispanic ethnicity, n (%) | 67 (4.6) | 13 (5.0) | 31 (6.3) | 5 (4.1) | 4 (2.3) | 14 (3.5) |
| Comorbidities, n (%) | ||||||
| Hypertension | 635 (43.8) | 154 (59.0) | 220 (44.7) | 49 (39.8) | 63 (36.6) | 149 (37.2) |
| Diabetes mellitus | 234 (16.1) | 61 (23.4) | 92 (18.7) | 20 (16.3) | 20 (11.6) | 41 (10.2) |
| Obesity | 427 (29.5) | 92 (35.2) | 156 (31.7) | 49 (39.8) | 35 (20.3) | 95 (23.7) |
| Cardiovascular disease | 210 (14.5) | 62 (23.8) | 72 (14.6) | 15 (12.2) | 20 (11.6) | 41 (10.2) |
| Obstructive lung disease | 310 (21.4) | 73 (28.0) | 109 (22.2) | 25 (20.3) | 31 (18.0) | 72 (18.0) |
| Interstitial lung disease | 81 (6.0) | 17 (6.5) | 25 (5.1) | 8 (6.5) | 9 (5.2) | 22 (5.5) |
| Vaccination status, n (%) | ||||||
| Unvaccinated or prevaccine | 938 (64.7) | 261 (100) | 492 (100) | 102 (82.9) | 40 (23.3) | 43 (10.7) |
| Partially vaccinated | 50 (3.5) | 0 (0) | 0 (0) | 19 (15.4) | 14 (8.1) | 17 (4.2) |
| Two doses mRNA or one dose J&J | 228 (15.7) | 0 (0) | 0 (0) | 2 (1.6) | 90 (52.3) | 136 (33.9) |
| Additional doses | 233 (16.1) | 0 (0) | 0 (0) | 0 (0) | 28 (16.3) | 205 (51.1) |
| SARS-CoV2 diagnosis method, n (%) | ||||||
| PCR | 1126 (77.7) | 246 (94.3) | 426 (86.6) | 100 (81.3) | 129 (75.0) | 225 (56.1) |
| Antigen/rapid test | 123 (8.5) | 0 (0) | 0 (0) | 0 (0) | 1 (0.6) | 122 (30.4) |
| Other or unknown | 200 (13.8) | 15 (5.7) | 66 (13.4) | 23 (18.7) | 42 (24.4) | 54 (13.5) |
J&J, Johnson and Johnson/Janssen